Comprehensive characterization of transcript diversity at the human *NODAL* locus

Scott D Findlay^{1,2}, Lynne-Marie Postovit^{1*}

1. University of Alberta. Edmonton, Alberta, Canada.
Department of Oncology, Faculty of Medicine and Dentistry.
2. The University of Western Ontario. London, Ontario, Canada.
Department of Anatomy and Cell Biology, Schulich School of Medicine and Dentistry.

*Corresponding author contact information:

Dr. Lynne-Marie Postovit

5-142E Katz Group Centre for Pharmacy and Health Research

University of Alberta

114th St and 87th Ave

Edmonton, AB, Canada

T6G 2E1

780-492-6342

postovit@ualberta.ca

Abstract:

NODAL, a morphogen belonging to the transforming growth factor beta (TGF β) superfamily, is essential during embryogenesis where it induces axis formation and left-right asymmetry. *NODAL* is also required for the maintenance of human embryonic stem cell pluripotency, and emerges in many cancer types concomitant with metastasis and therapy resistance. Several enhancer elements have been shown to regulate mouse *Nodal* expression and studies have delineated mechanisms by which mRNA splicing and translation of *NODAL* homologues are regulated in model organisms. However, little is known regarding the co-transcriptional and post-transcriptional processing of human *NODAL*. Herein, we describe hitherto unreported RNAs which are transcribed from the *NODAL* locus, including an antisense transcript, a circular transcript, and multiple splice variants. These transcripts demonstrate the complexity of *NODAL* expression and highlight the need to consider each *NODAL* variant when attempting to quantify or target this morphogen.

Introduction:

The transforming growth factor-beta (TGF- β) superfamily member nodal growth differentiation factor (human gene symbol: *NODAL*, NCBI gene ID: 4838) plays essential roles in early embryonic development and is reactivated in cancers. *Nodal* is aptly named after its discovery in the mouse node in gastrula-stage embryos¹. *Nodal* has been well studied in numerous vertebrate embryos and *in vitro* models of early development²⁻⁵. These studies have shown that *Nodal* promotes epiblast expansion and maintenance in blastocyst stage embryos⁶, directs the specification of the distal visceral endoderm (DVE) after implantation⁷, establishes the proximal-distal⁸ and anterior-posterior^{8,9} axes, influences mesendoderm differentiation during gastrulation (reviewed in⁵), and establishes left-right asymmetry^{10-11,13}.

Owing to practical and ethical limitations concerning research on human embryos, human-specific study of *NODAL* biology has generally been limited to cultured human embryonic stem (hES) cells where *NODAL* helps maintain pluripotency¹⁴, and blocks differentiation toward neuroectoderm lineages¹⁵. In addition, active SMAD2/3 downstream of *NODAL* (and other TGF- β s) also mediates cell fate decisions during mesendoderm differentiation¹⁶⁻¹⁹.

NODAL expression in cancer was first identified by Postovit and Topczewska and colleagues in the aggressive C8161 human melanoma cell line²⁰. These cells were able to induce ectopic outgrowths or a complete secondary axis after injection into zebrafish embryos at the blastocyst

stage and *NODAL* was identified as the primary factor responsible for this induction. Since this pioneering discovery, *NODAL* has been shown to affect numerous tumour phenotypes in experimental models of several human cancers including cancers of the breast²¹⁻²⁵, prostate^{26,27}, ovary^{28,29}, and pancreas³⁰, as well as glioma^{31,32}, glioblastoma³³, endometrial cancer³⁴, hepatocellular carcinoma³⁵, and choriocarcinoma^{24,36,37}. In these models, *NODAL* is generally pro-tumourigenic and impacts numerous processes including proliferation and apoptosis, migration and invasion, epithelial-to-mesenchymal transition (EMT), angiogenesis, and metastasis (reviewed in⁴).

There is also strong correlative evidence of a link between high *NODAL* expression and poor clinical outcome in numerous cancers. For example, in a study of over 400 breast cancer patients, *NODAL* protein levels correlated positively with tumour stage and grade, independently of estrogen receptor/progesterone receptor (ER/PR) or HER2 status³⁸. Moreover, a recent meta-analysis of *NODAL* expression in human cancers originating from 11 different tissues and including more than 800 patients revealed significantly higher *NODAL* expression in cancerous tissue relative to healthy control tissue³⁹.

While transcriptional regulation of *Nodal* has been extensively studied in the mouse, and many enhancers have been identified^{10,40-48}, little is known regarding the co-transcriptional and post-transcriptional processing of *NODAL* transcripts. We recently reported how such regulation is relevant in our discovery of a genetically regulated alternatively spliced *NODAL* transcript in human pluripotent stem cells⁴⁹. This discovery, along with a previous report of inconsistent detection of *NODAL* transcripts when probing different exons⁵⁰, prompted us to perform a comprehensive quantitative analysis of human *NODAL* transcripts across human cell lines commonly employed to model *NODAL* biology. Herein, we describe multiple novel RNAs transcribed from the *NODAL* locus, including an antisense transcript, a circular transcript, and multiple splice variants. These RNAs can confound the interpretation of expression studies, particularly given variable levels of *NODAL* expression that can occur in response to different culture conditions.

Results:

Several studies have suggested that *NODAL* is essential for the maintenance of pluripotency in hES cells and a large-scale study demonstrated that *NODAL* and *NANOG* expression were highly correlated across numerous hES cell lines⁵¹. However, few have thoroughly examined endogenous *NODAL* expression in response to various culture conditions. In our first attempts to use droplet digital PCR (ddPCR) assays for absolute quantification of *NODAL* in human embryonic stem cells, we made the surprising discovery that *NODAL* expression levels can vary dramatically in H9 hES cells. For example, one pair of samples differed in total *NODAL* transcript by over 3,000-fold, with only 26 copies of total *NODAL* transcript detected for the low-expressing sample in cDNA from 100 ng of total RNA (Fig. 1a,b).

To experimentally investigate possible factors that may influence *NODAL* transcript levels, we focused on cell culture media, as either defined media such as mTESR-1, or media conditioned by mouse embryonic fibroblasts (MEFs), are regularly employed in the maintenance of hES cells. H9 hES cells adapted for culture in defined conditions (mTESR-1) expressed low levels of total *NODAL* transcript, but displayed markedly increased *NODAL* transcript levels after being switched to MEF-conditioned media (MEF-CM) for only several days (Fig. 1c). The reciprocal effect was also observed: when cells continually passaged in MEF-CM were returned to defined conditions, *NODAL* levels decreased by approximately the same factor as it had increased previously (Fig. 1c). Notably, cells under both conditions expressed similar levels of markers of pluripotency (Fig. 1d) and had morphologies typical of pluripotent stem cells (Fig. 1e). Hence, *NODAL* levels seem to fluctuate even when pluripotency is maintained.

We next sought to examine the exact composition of *NODAL* transcripts in human embryonic stem cells. We recently reported that a single nucleotide polymorphism (SNP) modulates a novel alternative splicing event for human *NODAL* in hES cells⁴⁹. Specifically, the minor allele of SNP rs2231947 in *NODAL*'s second intron contributes to splicing of a 116-base pair cassette alternative exon (Fig. 2). This splicing event was associated with both the sex of hES cell lines, as well as *XIST* RNA levels in female hES cell lines, but transcripts containing the alternatively spliced exon have yet to be fully characterized. Like total *NODAL* levels, the proportion of *NODAL* transcripts containing the alternative exon was also variable between sub cultures, and was higher in cells cultured in defined media relative to MEF-CM (Supplementary Fig. S1). For the remainder of this

study, we aimed to always (when possible) distinguish the constitutively spliced (canonical) NODAL isoform from the newly discovered alternatively spliced NODAL variant isoform.

We first used rapid amplification of cDNA ends (RACE) to determine both the 5' and 3' termini. The 5' end marks the transcriptional start site(s) and defines the length of the 5' untranslated region (UTR) while the 3' end defines the 3' UTR and polyadenylation site(s) utilized. Standard 5' RACE was conducted using a primer designed to reverse transcribe total NODAL, and a single product was obtained. Sequencing revealed a 5' end 14 bases upstream of the annotated NODAL translational start codon, and 28 bases downstream of the annotated NODAL transcriptional start site in RefSeq (NM_018055.4). In contrast, several different products were detected for RNA reverse transcribed with a primer specific to the alternative NODAL exon (Supplementary Fig. S2). Two of these products revealed 5' ends within the first exon of NODAL, but likely resulted from incompletely reverse-transcribed RNA. Interestingly, a third band revealed utilization of a novel upstream first exon spliced directly to exon 2. Subsequent analysis with RNA ligase mediated (RLM) 5' RACE specific for capped mRNA ends confirmed a single major product for NODAL transcripts corresponding to transcriptional start at position -14 (Fig. 3a). A true 5' end was also confirmed within the alternative upstream first exon using a separate primer set (Supplementary Fig. S2). However, it was not possible to *specifically* assess whether constitutively or alternative spliced NODAL isoforms contributed to any given 5' end using the RLM method.

For processed mRNA transcripts, 3' ends are marked by the start of a polyA tail approximately 15-30 nucleotides downstream of a polyadenylation signal (PAS) (reviewed in ⁵²). Analysis of NODAL's constitutive terminal exon 3 for common polyadenylation signals revealed two AUUAAA motifs and a single AAUAAA motif (Fig. 3c). These two motifs are the most commonly utilized for polyadenylation of human transcripts ⁵³, although other less-frequently utilized putative PASs were also found in the annotated 3' UTR. 3' RACE for total NODAL transcript revealed roughly equal utilization of either a more proximal AUUAAA site, or a more distal AAUAAA site (Fig. 3b). NODAL variant transcripts also utilized the same polyadenylation sites, but in a manner highly skewed toward the distal site (Fig. 3d).

We were next interested in comparing the performance of assays targeting different regions of the NODAL transcript. Since ddPCR is absolutely quantitative, it permitted direct comparison of the abundance of different targets and was selected as our PCR platform. For the same "high NODAL"

sample from Fig. 1, the number of transcripts detected did not differ substantially when targeting different regions of the transcript: There was less than a 1.5-fold difference seen when targeting the exon 2 - exon 3 junction, exon 1 – exon 2 junction, or exon 2 only (Fig. 4a). However, for the “low NODAL” H9 sample, signal was much higher when probing exon 2 only, relative to either of the exon junctions (Fig. 4a). “No reverse transcription” controls demonstrated this signal was specific to RNA and did not result from genomic DNA or other DNA contamination (Supplementary Fig. S3). The lack of increased signal within exon 2 for the “high NODAL” sample suggests that exon 2 is not more efficiently reverse transcribed, but instead that additional transcript(s) sharing sequence with exon 2 may exist. Unless co-regulated, these would make a higher relative contribution to total signal when NODAL levels are low. A survey of human RNAs from Genbank⁵⁴ revealed AK001176 as a candidate transcript that completely encompasses exon 2 of *NODAL* (Fig. 4b). We developed a ddPCR assay specific to AK001176 unable to detect spliced full-length *NODAL* and found that polyadenylated AK001176 was expressed in hES cells (Fig. 4c). AK001176 was transcribed in the antisense direction relative to full-length *NODAL* and can therefore be classified as a natural antisense transcript (NAT) to *NODAL* (Supplementary Fig. S4). Interestingly, AK001176 was also alternatively polyadenylated and contains an open reading frame that may code for a protein (Supplementary Fig. S4).

We were also interested in testing for the potential presence of other transcripts containing exon 2 sequence and discovered that *NODAL* exon 2 was an excellent candidate to form a circular RNA. Circular RNA occurs when the 5’ splice donor site of an intron forms a “back splice” with an upstream 3’ splice acceptor site of the same or other exons in the transcript⁵⁵. Relative to splice sites in general, it has been shown that circular RNA splice sites are more likely to be flanked by upstream and downstream intronic Alu repeat elements and that these genomic elements are more likely to be in opposite orientations. Single circularized exons were also found to be formed from some of the longest of all human exons, with an average length of 690 nucleotides⁵⁵. In addition to constitutive exon 2 of *NODAL* being an extremely long exon (698 nucleotides), there are two pairs of Alu repeats in opposite orientations in the intronic sequences flanking *NODAL* exon 2 (Fig. 4d). We used divergent PCR to determine if a circular RNA was present and detected a single circular RNA product formed by back splicing of exon 2 of *NODAL* (Fig. 4e).

Having now detected novel antisense and circular transcripts in addition to our previous discovery of an alternatively spliced transcript, we were motivated to profile all of these *NODAL* locus RNAs

across several human cell lines that have been used to model *NODAL* biology. To this end, we assembled a panel that included breast cancer cell lines (both Estrogen Receptor positive and negative), where *NODAL* has been extensively modelled^{22-24,56}, the C8161 melanoma cell line where *NODAL* was first characterized in cancer²⁰, HEK 293 cells of embryonic origin, and H9 hES cells (cultured in MEF-CM). All regions of full-length *NODAL* and all of the newly discovered transcripts were profiled in parallel using ddPCR. For all cancer cell lines assayed, extremely low (or undetectable) levels of *NODAL* transcript (≤ 2 copies per 100 ng total RNA input) were detected using assays spanning either exon-exon boundary. In contrast, signal detected within exon 2 ranged from 316 to 1,786 copies of transcript per 100 ng total RNA input (Fig. 5). However, this assay is not specific for full-length *NODAL* and also detects the AK001176 NAT. Indeed, very similar levels of transcript were detected for AK001176 and the *NODAL* exon 2 assay across all cancer cell lines. Specifically, the maximum ratio of *NODAL* exon 2 signal to AK001176 signal among cancer cell lines was 1.6-to-1, with an average of 1.4-to-1. These two signals were also highly correlated, with variability in AK001176 signal explaining 96% of the variability in exon 2 signal among cancer cell lines (Fig. 5b). Similar levels of AK001176 transcript were detected between H9 hES and cancer cells, while the circular *NODAL* RNA was detected only in H9 hES cells. Collectively, these results suggest that bulk cancer cell lines express very little processed (spliced) *NODAL* transcript, and that use of assays confined to exon 2 is inappropriate for the detection of full-length *NODAL*, owing to consistent expression of a *NODAL* NAT containing sequence identical to the entirety of *NODAL* exon 2.

Discussion:

In this work, we have characterized and quantified both known and novel transcript isoforms expressed from the human *NODAL* locus in cell lines where this gene is commonly studied. Specifically, in addition to a previously identified genetically-regulated splice variant⁴⁹, we detected an alternative transcriptional start site and first exon upstream of constitutive exon 1, alternative polyadenylation site usage, a circular RNA formed by back-splicing of exon 2, and a natural antisense transcript encompassing the exon 2 locus. Collectively, these results point to complex regulation of *NODAL* gene expression at the RNA level. The discoveries reported here should be used to refine assay design for more specific and accurate *NODAL* detection, and to improve strategies designed to experimentally (and potentially therapeutically) target *NODAL*.

We also characterized multiple aspects of the full-length *NODAL* transcripts, discovering fairly uniform short 5' UTR usage (although a rare alternative 5' UTR was also detected), and alternative polyadenylation at two PAS sites in the 3' UTR. These aspects of *NODAL* processing present interesting opportunities to advance understanding of *NODAL* regulation, as both alternative transcriptional start site (TSS) utilization as marked by the 5' UTR, and alternative polyadenylation (APA) marked by the 3' UTR can influence mRNA dynamics including translation⁵⁷⁻⁵⁹. Furthermore, global changes in 3' UTR length resulting from APA occur in both early embryonic development⁶⁰⁻⁶² and in oncogenesis⁶³⁻⁶⁵—both highly relevant cell contexts for *NODAL*.

The apparent enrichment of an alternative first exon and skewed polyadenylation site usage for the *NODAL* variant relative to constitutively spliced *NODAL* suggests there may be coordinated regulation of the *NODAL* variant transcript that extends beyond the splice donor site formed by the rs2231947 T allele in cis (Fig. 2 and Fig. 3). However, this apparent enrichment may also result from technical issues such as differential reverse transcription efficiencies of distinct transcripts. The apparent coordination with polyadenylation is interesting given that a link between alternative polyadenylation and alternative splicing has been described, but only for 3' terminal exon selection and intronic polyadenylation sites^{66,67}.

The ability to quantitatively profile expression levels of all *NODAL* locus RNAs was enhanced by ddPCR. As an absolutely quantitative method, resultant transcript levels are not influenced by PCR efficiencies or dependent on the use of standard curves. Furthermore, duplexed ddPCR assays were used to easily distinguish constitutively spliced *NODAL* transcripts from those containing the alternative cassette exon (Supplementary Fig. S1).

Our finding that *NODAL* transcripts were not consistently highly expressed in hES cells was surprising given that *NODAL* signalling is generally thought to be essential for hES cell pluripotency^{14,17} and consistently high *NODAL* expression has been reported for this cell type⁵¹. Our “low *NODAL*” cells maintained typical pluripotent stem cell morphology and expression of markers of pluripotency (Fig. 1e). It is possible that low *NODAL* levels are indicative of sub-optimal cultures poised for (or already undergoing) early differentiation. In this vein, *NODAL*, *LEFTY1*, and *LEFTY2* displayed some of the most rapid down-regulation upon spontaneous hES cell differentiation in a small panel of pluripotency markers⁶⁸. It is also possible that high *NODAL*

mRNA expression is not strictly required for the maintenance of pluripotency, and that NODAL is either preferentially translated into protein, or that there are redundant or compensatory mechanisms that can otherwise sustain pluripotency in certain culture conditions when NODAL mRNA levels are low. Our results are consistent with the notion that a pluripotent gene expression signature is not static or universal, but rather partially stochastic, and that the combinations of active transcription factor networks and signalling pathways that can support the pluripotent state can drift with culture conditions and microenvironmental factors, between cell lines, and due to other unknown variables. Indeed, it has been suggested that there exists a spectrum or continuum of pluripotent states both *in vitro* and *in vivo* (reviewed by ⁶⁹). In our study, the observed variability in hES cell NODAL transcript levels was certainly staggering. That NODAL transcript levels were dramatically and reversibly influenced by culture conditions may be an indication that more general differences exist between hES cells cultured in MEF-conditioned serum replacement-based media and in more defined media. In general, some differences in hES cells cultured under varying conditions have been observed ^{70,71}. However, very little work has directly compared culture of hES cells in MEF-CM to culture in defined media such as mTESR ⁷². Perhaps surprisingly, there is a striking absence of work involving comprehensive and quantitative profiling of hES gene expression signatures between MEF-CM and defined media, to investigate to what extent such media may potentiate distinct pluripotent states *in vitro*.

In addition to the unexpectedly low levels of NODAL transcript sometimes observed in hES cells, we also made the surprising discovery of especially low *NODAL* expression at the transcript level across numerous human cancer cell lines. The extremely low levels and often absence of any NODAL transcript reported here for cell lines such as C8161 aggressive melanoma and MDA-MB-231 triple-negative breast cancer are inconsistent with functional studies in these cell lines where NODAL knockdown, mediated through either RNA interference ^{22,25}, or inhibition of endogenously expressed protein ⁷³ resulted in profound phenotypic effects. Notably, NODAL mRNA expression was not assessed in these papers, so it is difficult to tell whether the detectable and functionally relevant levels of NODAL protein reported in these studies were expressed from cells with considerably higher NODAL mRNA levels. There are several possibilities for this apparent discrepancy. First, it is possible that NODAL mRNA is preferentially stabilized or translated, generating high levels of protein from a limited transcript pool. Second, it is possible that a technical issue such as NODAL-specific extremely inefficient reverse transcription limits

the detection of transcript, although it is especially important to emphasize that high levels of *NODAL* transcript were routinely detected in hES cell samples analyzed in parallel. Third, it is possible that *NODAL* mRNA steady state levels are highly heterogeneous between subcultures of cancer cell lines or that this transcript is only present in a very rare subpopulation (for example cancer stem cells) such that the levels are diluted in bulk cultures. Finally, in zebrafish, mRNA of the maternal *Nodal* homolog *sqt* is prevalent as unspliced pre-mRNA⁷⁴⁻⁷⁶. It is possible that cancer cells similarly retain *NODAL* mRNAs in this unprocessed state, which would not be detectable using primers spanning introns. Regardless, the quantitative profiling performed here certainly helps explain some of the previously reported challenges associated with detection and modelling of *NODAL* in human cell lines⁵⁰.

Consistent with our findings, at least one other group has reported undetectable *NODAL* transcript levels in MDA-MB-231 cells when using a real time PCR assay spanning an exon-exon boundary⁴⁷. One other study has directly compared *NODAL* expression levels between two cancer cell lines and hES cells with multiple assays, although this analysis was conducted using semi-quantitative end-point PCR⁵⁰. For the C8161 cell line, an assay crossing the exon 2 - exon 3 boundary resulted in a low intensity band. In contrast, an assay internal to exon 2 yielded a band of much higher intensity. This result is consistent with those presented here, which revealed that this higher signal may at least partially result from confounded detection of the AK001176 NAT sharing sequence with exon 2 of *NODAL*. The increased signal from assays internal to exon 2 is likely not the result of higher reverse transcription efficiency in this region of the transcript since signal was fairly uniform across all regions of the transcript in an H9 sample with high *NODAL* expression. A major conclusion of this work is that assays targeting only exon 2 of *NODAL* are not specific to full-length spliced *NODAL* transcripts and are thus inappropriate for *NODAL* transcript detection. Unfortunately, such assays have already been widely employed when assessing *NODAL* mRNA levels (e.g.^{22,26,30,50,56,77-80}). Going forward, it is highly recommended that specific assays for the antisense transcript, circular RNA, and *NODAL* splice variants be employed to untangle the contributions of each transcript to any overall change in expression measured by the assays internal to exon 2, as conducted in Fig. 5. As an example, it will be interesting for future studies to explore whether these three transcripts show similar responses to altered microenvironments.

In conclusion, we believe the *NODAL* locus is an interesting example of the capacity the cell has for complex RNA transcription and processing. There is reason to believe that *NODAL* is more the

rule than the exception in this regard, as genome-wide analyses of processes such as alternative splicing and alternative polyadenylation have revealed multiple transcripts for the vast majority of protein coding genes⁸¹⁻⁸⁴. Still, the full-length nature and functional consequences of many alternatively processed transcripts are only beginning to be appreciated on a genome wide scale⁸⁵. Of course, the alternative processing of RNAs has major impacts on either the sequence or levels of resulting protein, which in turn affect cellular function and phenotypes. In order to advance our general understanding of gene expression and function, we must move beyond the simple conceptualization of a single RNA corresponding to each gene, and fully explore the staggeringly complex intracellular world at the RNA level.

Methods:

Web logos

Sequence logos in Figure 2 were created using WebLogo version 2.8.2 (<http://weblogo.berkeley.edu/> and^{86,87}).

Microscopy

Pictures of H9 hES cells in different media were taken using EVOS FL Cell Imaging System (Thermo Fisher) with either 4X, 10X, or 20X objective lenses. Contrast and other image properties were adjusted so that cells and colony boundaries were more easily visible.

Cell culture

H1 and H9 lines were purchased from WiCell (Madison, Wisconsin, USA). H9 cells were maintained on irradiated CF-1 Mouse Embryonic Fibroblasts (MEFs) (GlobalStem; Gaithersburg, Maryland, USA) with standard media composed of DMEM/F-12 with GlutaMAXTM (Thermo Fisher Scientific; Waltham, Massachusetts, USA), 20% KnockOutTM serum replacement (Thermo Fisher), 1X non-essential amino acids (Thermo Fisher), 0.1 mM 2-mercaptoethanol (Thermo Fisher), and 4 ng/ml of basic fibroblast growth factor (Thermo Fisher). H1 cells were maintained in feeder-free conditions that consisted of growth on a Geltrex matrix (Thermo Fisher) with either defined mTeSR1 media (Stem Cell Technologies; Vancouver, British Columbia, Canada), or CF-1 MEF-conditioned media as indicated. All hES cells were passaged manually and always harvested from feeder-free culture conditions. HEK 293 (ATCC; Manassas, Virginia, USA) cells were maintained in DMEM (Thermo Fisher) supplemented with 10% fetal bovine serum (Thermo

Fisher). T47D, MCF7, and MDA-MB-231 breast cancer cells, and C8161 melanoma cells⁸⁸, were cultured in RPMI supplemented with 10% FBS (Thermo Fisher). SUM149 cells were cultured in media consisting of Ham's F12 with 5% heat inactivated FBS, supplemented with HEPES, Hydrocortisone, and Insulin according to instructions provided by Asterand Bioscience (Detroit, USA). All cells were cultured at 37°C with 5% CO₂ supplementation in a humidified environment.

RNA extraction

Total RNA was isolated from cultured cells using the PerfectPure RNA Cultured Cell Kit (5-Prime; Hilden, Germany) or the RNeasy mini kit (Qiagen; Hilden, Germany), including on-column DNase treatment, and quantified with the Epoch plate reader (Biotek; Winooski, Vermont, USA).

cDNA synthesis (for non-RACE analyses)

Total RNA was reverse transcribed with the high capacity cDNA reverse transcription kit (Applied Biosystems; Foster City, California, USA) following manufacturer's instructions. Random hexamers were generally used to prime synthesis by reverse transcriptase. Reactions where oligo dT was used in place of random hexamers are indicated. "No RT" control reactions included RNA template and all components except reverse transcriptase enzyme. Figures with "transcripts detected per x ng cDNA loaded" axes refer to the amount of cDNA used based on the quantification of RNA. A separate quantification of cDNA was not performed.

Droplet digital PCR (ddPCR)

ddPCR for total NODAL was conducted using Taqman primer probe assays Hs00415443_m1 (exon 1 – exon 2), Hs00250630_s1 (exon 2 only), or Hs01086749_m1 (exon 2 – exon 3) (Applied Biosystems). Where not indicated, Hs00415443_m1 (exon 1 – exon 2) was used for detection of total NODAL transcript.

The following primers and probes were used for duplexed detection of NODAL splice variants, with fluorophores, internal quenchers, and terminal quenchers flanked by forward slashes.

<i>NODAL</i> dual F:	GACCAACCATGCATACATC
<i>NODAL</i> dual R:	AACAAGTGGAAGGGACTC
Alternative exon probe:	/56-FAM/CCTGCTGTC/ZEN/CAAGGTCATAT/3IABkFQ/
Constitutive exon probe:	/5HEX/CTGGTAACG/ZEN/TTTCAGCAGAC/3IABkFQ/

Droplets that were both FAM⁺ and HEX⁺, corresponding to the *NODAL* variant, were quantified using Quantasoft software. Since constitutive *NODAL* was FAM⁻ and HEX⁺, and could therefore be co-amplified in droplets containing *NODAL* variant transcript, constitutive *NODAL* was calculated manually using the equation: copies/ 20 μ L sample = $-\ln(1-p) \times 20,000 / 0.85$. where ‘p’ is the proportion of positive droplets defined as FAM⁻HEX⁺ droplets / (FAM⁻HEX⁺ droplets + empty droplets), and 0.85 nL is the average volume of a droplet as used by QuantaSoft (Bio-rad)⁸⁹.

For detection of the *NODAL* NAT transcript, the following primers and probe were used:

NODAL NAT F: TTAATAGCAAAGCTAGAGCC

NODAL NAT R: CATGCATACATCCAGGTG

NODAL NAT FAM: /56-FAM/CCCAAGGCC/ZEN/AGCTTACTG/3IABkFQ/

For detection of the *NODAL* circular exon 2 transcript, the following primers and probe were used:

NODAL ex2 circ F: GAGTTTCATCCGACCAAC

NODAL ex2 circ R: AGTCAAAAGCAAACGTCC

NODAL ex2 circ FAM: /56-FAM/CCACTGCCA/ZEN/CATCTGGAT/

For all ddPCR assays, primers were used at a final concentration of 900 nM and probes were used at a final concentration of 250 nM.

For the dual *NODAL* splice variant assay, a “two-step” PCR was used with the following conditions:

- 1) 95° C 10 min
- 2) 94° C 30 sec
- 3) 50° C 1 min
- 4) 72° C 2 min. Return to step 2 for 40 total cycles.
- 5) 98° C 10 min

For all other ddPCR assays, the following cycling conditions were used:

- 1) 95° C 10 min
- 2) 94° C 30 sec
- 3) 55° C 1 min. Return to step 2 for 40 total cycles.
- 5) 98° C 10 min

Real time PCR

Real time PCR was performed using Taqman gene expression master mix (Applied Biosystems) and Taqman gene expression assays for POU5F1 (also known as OCT4) (Hs04260367_gH), NANOG (Hs04260366_g1), SOX2 (Hs01053049_s1), RPLP0 (4333761), and TBP (Hs99999910_m1). Expression was normalized to both RPLP0 and TBP using the $\Delta\Delta C_t$ method.

RNA ligase mediated (RLM) 5' RACE

RLM 5' RACE was performed with the FirstChoice RLM-RACE kit (Ambion) according to manufacturer's instructions. 10 μ g of total RNA from H1 or H9 hES cells was used. Reverse transcription was performed at 50°C for one hour using random decamers provided. No-TAP, no-RT, and no-template control reactions were included to ensure specificity of products obtained. Subsequent PCR reactions were performed with AmpliTaq Gold 360 Master Mix with 1 μ L of cDNA per reaction. An annealing temperature of 55°C was used for all reactions.

The following primers were used:

5' RACE outer primer F:	GCTGATGGCGATGAATGAACACTG
5' RACE inner primer F:	CGCGGATCCGAACACTGCGTTTGCTGGCTTTGATG
NODAL exon2 outer R:	TCCACTCAGGCTGCAAATGGAC
NODAL exon2 inner R:	AACGTCCAGTTCTGCCCCATCCAC
NODAL alt. exon1 outer R:	GGCTGGTGGAAAATCTCAATGGC
NODAL alt. exon1 inner R:	AGCACCCCTGGCCCTACCAAATAC

Standard 5' RACE

Standard 5' RACE analysis was conducted using the 5' RACE System for Rapid Amplification of cDNA Ends (Thermo Fisher) following manufacturer's instructions. Three (3) μ g of total RNA was used for each sample. Reverse transcription was performed for 50 minutes. All primers for first and second round PCR were used at a final concentration of 400 nM. An annealing temperature of 56°C was used for all reactions.

Primers used for reverse transcription:

total <i>NODAL</i> 5' RACE GSP1:	GAAAATCTCAATGGCAAGTGAG
<i>NODAL</i> variant 5' RACE GSP1:	CATGGAGGATATATTGCAAGTC

Primers used for first round PCR:

total *NODAL* 5' RACE GSP2: CCATGCCAGATCCTCTTGTTG

NODAL variant 5' RACE GSP2: TCCCATATGACCTTGGACAGC

Abridged anchor primer (AAP): GGCCACGCGTCGACTAGTACGGGGIIGGGIIGGGIIG

The same primer targeting constitutive exon 2 of *NODAL* was used for second round nested PCR analysis of both total *NODAL* and *NODAL* variant transcripts:

total *NODAL* 5' RACE nested: GAAGGAGAAGTCAAAAGCAAACG

Abridged universal amplification primer (AUAP): GGCCACGCGTCGACTAGTAC

3' RACE

For 3' RACE, 2 µg total RNA was used for reverse transcription. Random primers were substituted for an oligo dT-adapter mix of “lock-dock”⁹⁰ primers with either A, G, or C as the most 3' base:

dT adapter primer R A: GGCCACGCGTCGACTAGTACTTTTTTTTTTTTTTTTTTA

dT adapter primer R G: GGCCACGCGTCGACTAGTACTTTTTTTTTTTTTTTTTTG

dT adapter primer R C: GGCCACGCGTCGACTAGTACTTTTTTTTTTTTTTTTTTC

Each primer was used at a final concentration of 167 nM for a total primer concentration of 500 nM. 2 µL (equivalent to 200 ng RNA) of each cDNA reaction was used for subsequent PCR performed with AmpliTaq Gold 360 Master Mix. Primers were used at a final concentration of 200 nM. An annealing temperature of 54°C was used for all reactions.

Forward primers (variable for each target):

total *NODAL* 3' RACE F1: TCTCCAAAGTAGTCTGTGTGTGAC

total *NODAL* 3' RACE F2 nested: TCCCCCTCCCCAAAGATTAAGG

NODAL variant 3' RACE F1: CTGCTGTCCAAGGTCATATGGG

NODAL variant 3' RACE F2 nested: AATATATCCTCCATGCCAAGCCTC

NAT 3' RACE F1: CGCTTCAGCCACTTGGAGAG

NAT 3' RACE F2 nested: ACCTCCAAAACCATGCTGCC

Reverse primer (identical for each target):

Abridged universal amplification primer (AUAP) R: GGCCACGCGTCGACTAGTAC

Other (non-RACE) end-point PCR

AmpliTaq Gold 360 Master Mix (Applied Biosystems) was used for all end-point PCR analyses. Primers were used at a final concentration of 250 nM.

For the *NODAL* exon 2 divergent PCR to detect circular RNA, the following primers were used:

NODAL divergent exon2 F1: TACCCCAAGCAGTACAACGC
NODAL divergent exon2 R1: GTCCAGTTCTGCCCATCCAC
NODAL divergent exon2 F2: GTGAGGGCGAGTGTCTAATC
NODAL divergent exon2 R2: TTGGCTCAGGAAGGAGAAGTC

An annealing temperature of 55°C and an extension time of 1 minute were used.

To detect the *NODAL* NAT, the following primers were used:

NAT F: GCAAGAGCTATGGTGGTTGTG
 NAT R: TAGCAAAGCTAGAGCCCTGTC

An annealing temperature of 54°C and an extension time of 2 minutes were used.

Cloning and sequence analysis:

All RACE and other end-point PCR products amplified with custom primers were cloned into the pCR 4-TOPO plasmid with TOPO TA cloning for sequencing kit (Thermo Fisher). Cloning reactions were transformed into One Shot TOP10 Chemically Competent *E. coli* (Thermo Fisher). Individual clones were selected with Kanamycin and propagated for mini prep of plasmid DNA using the High-Speed Plasmid Mini Kit (Geneaid/FroggaBio; Toronto, Ontario, Canada). Multiple clones were sequenced for each product to confirm amplicon identities. Sanger sequencing using the plasmid-specific M13R or M13F primers was conducted by the Molecular Biology Service Unit at the University of Alberta (Edmonton, Canada), or the London Regional Genomics Centre at Western University (London, Canada).

References

1. Zhou, X., Sasaki, H., Lowe, L., Hogan, B. L. & Kuehn, M. R. Nodal is a novel TGF-beta-like gene expressed in the mouse node during gastrulation. *Nature* **361**, 543–547 (1993).
2. Shen, M. M. Nodal signaling: developmental roles and regulation. *Development* **134**, 1023–1034 (2007).
3. Schier, A. F. Nodal Morphogens. *Cold Spring Harbor Perspectives in Biology* **1**, a003459–a003459 (2009).
4. Quail, D. F., Siegers, G. M., Jewer, M. & Postovit, L.-M. Nodal signalling in embryogenesis and tumourigenesis. *The International Journal of Biochemistry & Cell Biology* **45**, 885–898 (2013).

5. Bodenstine, T. M., Chandler, G. S., Seftor, R. E. B., Seftor, E. A. & Hendrix, M. J. C. Plasticity underlies tumor progression: role of Nodal signaling. *Cancer Metastasis Rev* **35**, 21–39 (2016).
6. Camus, A., Perea-Gomez, A., Moreau, A. & Collignon, J. Absence of Nodal signaling promotes precocious neural differentiation in the mouse embryo. *Developmental Biology* **295**, 743–755 (2006).
7. Mesnard, D. Nodal specifies embryonic visceral endoderm and sustains pluripotent cells in the epiblast before overt axial patterning. *Development* 1–9 (2006). doi:10.1242/dev.02413
8. Yamamoto, M. *et al.* Nodal antagonists regulate formation of the anteroposterior axis of the mouse embryo. *Nature* **428**, 387–392 (2004).
9. Kumar, A. *et al.* Nodal signaling from the visceral endoderm is required to maintain Nodal gene expression in the epiblast and drive DVE/AVE migration. *Developmental Biology* **400**, 1–9 (2015).
10. Brennan, J., Norris, D. P. & Robertson, E. J. Nodal activity in the node governs left-right asymmetry. *Genes & Development* **16**, 2339–2344 (2002).
11. Mercola, M. Left-right asymmetry: nodal points. *Journal of Cell Science* **116**, 3251–3257 (2003).
12. Adachi, H. *et al.* Determination of left/right asymmetric expression of nodal by a left side-specific enhancer with sequence similarity to a lefty-2 enhancer. *Genes & Development* **13**, 1589–1600 (1999).
13. Yamamoto, M. *et al.* Nodal signaling induces the midline barrier by activating Nodal expression in the lateral plate. *Development* **130**, 1795–1804 (2003).
14. Vallier, L. Activin/Nodal and FGF pathways cooperate to maintain pluripotency of human embryonic stem cells. *Journal of Cell Science* **118**, 4495–4509 (2005).
15. Vallier, L., Reynolds, D. & Pedersen, R. A. Nodal inhibits differentiation of human embryonic stem cells along the neuroectodermal default pathway. *Developmental Biology* **275**, 403–421 (2004).
16. Xi, Q. *et al.* A poised chromatin platform for TGF- β access to master regulators. *Cell* **147**, 1511–1524 (2011).
17. Vallier, L. *et al.* Activin/Nodal signalling maintains pluripotency by controlling Nanog expression. *Development* **136**, 1339–1349 (2009).
18. Kim, S. W. *et al.* Chromatin and transcriptional signatures for Nodal signaling during endoderm formation in hESCs. *Developmental Biology* **357**, 492–504 (2011).
19. Brown, S. *et al.* Activin/Nodal Signaling Controls Divergent Transcriptional Networks in Human Embryonic Stem Cells and in Endoderm Progenitors. *STEM CELLS* **29**, 1176–1185 (2011).
20. Topczewska, J. M. *et al.* Embryonic and tumorigenic pathways converge via Nodal signaling: role in melanoma aggressiveness. *Nat Med* **12**, 925–932 (2006).
21. Meyer, M. J. *et al.* Dynamic regulation of CD24 and the invasive, CD44posCD24neg phenotype in breast cancer cell lines. *Breast Cancer Res.* **11**, R82 (2009).
22. Quail, D. F. *et al.* Embryonic Morphogen Nodal Promotes Breast Cancer Growth and Progression. *PLoS ONE* **7**, e48237–12 (2012).
23. Quail, D. F. *et al.* Embryonic protein nodal promotes breast cancer vascularization. *Cancer Research* **72**, 3851–3863 (2012).
24. Quail, D. F., Zhang, G., Findlay, S. D., Hess, D. A. & Postovit, L. M. Nodal promotes invasive phenotypes via a mitogen-activated protein kinase-dependent pathway. *Oncogene*

- (2013). doi:10.1038/onc.2012.608
25. Kirsammer, G. *et al.* Nodal signaling promotes a tumorigenic phenotype in human breast cancer. *Seminars in Cancer Biology* **29**, 40–50 (2014).
26. Lawrence, M. G. *et al.* Reactivation of embryonic nodal signaling is associated with tumor progression and promotes the growth of prostate cancer cells. *Prostate* **71**, 1198–1209 (2011).
27. Vo, B. T. & Khan, S. A. Expression of nodal and nodal receptors in prostate stem cells and prostate cancer cells: autocrine effects on cell proliferation and migration. *Prostate* **71**, 1084–1096 (2011).
28. Xu, G. *et al.* Nodal Induces Apoptosis and Inhibits Proliferation in Human Epithelial Ovarian Cancer Cells via Activin Receptor-Like Kinase 7. *The Journal of Clinical Endocrinology & Metabolism* **89**, 5523–5534 (2004).
29. Fu, G. & Peng, C. Nodal enhances the activity of FoxO3a and its synergistic interaction with Smads to regulate cyclin G2 transcription in ovarian cancer cells. *Oncogene* **30**, 3953–3966 (2011).
30. Lonardo, E. *et al.* Nodal/Activin Signaling Drives Self-Renewal and Tumorigenicity of Pancreatic Cancer Stem Cells and Provides a Target for Combined Drug Therapy. *Cell Stem Cell* **9**, 433–446 (2011).
31. Hueng, D.-Y. *et al.* Inhibition of Nodal suppresses angiogenesis and growth of human gliomas. *J. Neurooncol.* **104**, 21–31 (2011).
32. Lee, C.-C. *et al.* Nodal promotes growth and invasion in human gliomas. *Oncogene* **29**, 3110–3123 (2010).
33. De Silva, T. *et al.* Nodal promotes glioblastoma cell growth. *Front Endocrinol (Lausanne)* **3**, 59 (2012).
34. Papageorgiou, I. *et al.* Expression of nodal signalling components in cycling human endometrium and in endometrial cancer. *Reprod Biol Endocrinol* **7**, 122–11 (2009).
35. Cavallari, C. *et al.* Role of Lefty in the anti tumor activity of human adult liver stem cells. *Oncogene* **32**, 819–826 (2013).
36. Munir, S. *et al.* Nodal and ALK7 inhibit proliferation and induce apoptosis in human trophoblast cells. *Journal of Biological Chemistry* **279**, 31277–31286 (2004).
37. Law, J., Zhang, G., Dragan, M., Postovit, L.-M. & Bhattacharya, M. Nodal signals via β -arrestins and RalGTPases to regulate trophoblast invasion. *Cell. Signal.* **26**, 1935–1942 (2014).
38. Strizzi, L. *et al.* Potential for the embryonic morphogen Nodal as a prognostic and predictive biomarker in breast cancer. *Breast Cancer Res.* **14**, R75 (2012).
39. Ning, F. *et al.* Expression and significance of Nodal in human cancers: a meta-analysis. *Int J Clin Exp Med* **8**, 20227–20235 (2015).
40. Norris, D. P. & Robertson, E. J. Asymmetric and node-specific nodal expression patterns are controlled by two distinct cis-acting regulatory elements. *Genes & Development* **13**, 1575–1588 (1999).
41. Norris, D. P., Brennan, J., Bikoff, E. K. & Robertson, E. J. The Foxh1-dependent autoregulatory enhancer controls the level of Nodal signals in the mouse embryo. *Development* **129**, 3455–3468 (2002).
42. Krebs, L. T. Notch signaling regulates left-right asymmetry determination by inducing Nodal expression. *Genes & Development* **17**, 1207–1212 (2003).
43. Raya, A. Notch activity induces Nodal expression and mediates the establishment of left-

- right asymmetry in vertebrate embryos. *Genes & Development* **17**, 1213–1218 (2003).
44. Vincent, S. D., Norris, D. P., Ann Le Good, J., Constam, D. B. & Robertson, E. J. Asymmetric Nodal expression in the mouse is governed by the combinatorial activities of two distinct regulatory elements. *Mechanisms of Development* **121**, 1403–1415 (2004).
45. Saijoh, Y. *et al.* Two nodal-responsive enhancers control left-right asymmetric expression of Nodal. *Dev. Dyn.* **232**, 1031–1036 (2005).
46. Papanayotou, C. *et al.* A novel nodal enhancer dependent on pluripotency factors and smad2/3 signaling conditions a regulatory switch during epiblast maturation. *Plos Biol* **12**, e1001890 (2014).
47. Arai, D. *et al.* An epigenetic regulatory element of the Nodal gene in the mouse and human genomes. *Mechanisms of Development* **136**, 143–154 (2015).
48. Sampath, K. & Robertson, E. J. Keeping a lid on nodal: transcriptional and translational repression of nodal signalling. *Open Biol.* **6**, 150200–8 (2016).
49. Findlay, S. D. & Postovit, L.-M. Brief Report: Common Genetic Variation in Chromosome 10 q22.1 Shows a Strong Sex Bias in Human Embryonic Stem Cell Lines and Directly Controls the Novel Alternative Splicing of Human NODAL which is Associated with XIST Expression in Female Cell Lines. *STEM CELLS* **34**, 791–796 (2016).
50. Strizzi, L., Hardy, K. M., Kirschmann, D. A., Ahrlund-Richter, L. & Hendrix, M. J. C. Nodal expression and detection in cancer: experience and challenges. *Cancer Research* **72**, 1915–1920 (2012).
51. Adewumi, O. *et al.* Characterization of human embryonic stem cell lines by the International Stem Cell Initiative. *Nature Biotechnology* **25**, 803–816 (2007).
52. Proudfoot, N. J. Ending the message: poly(A) signals then and now. *Genes & Development* **25**, 1770–1782 (2011).
53. Retelska, D., Iseli, C., Bucher, P., Jongeneel, C. V. & Naef, F. BMC Genomics. *BMC Genomics* **7**, 176–10 (2006).
54. Benson, D. A. *et al.* GenBank. *Nucleic Acids Research* **41**, D36–D42 (2012).
55. Jeck, W. R. *et al.* Circular RNAs are abundant, conserved, and associated with ALU repeats. *RNA* **19**, 141–157 (2013).
56. Quail, D. F. *et al.* Low oxygen levels induce the expression of the embryonic morphogen Nodal. *Mol. Biol. Cell* **22**, 4809–4821 (2011).
57. Tian, B. & Manley, J. L. Alternative polyadenylation of mRNA precursors. *Nat. Rev. Mol. Cell Biol.* 1–13 (2016). doi:10.1038/nrm.2016.116
58. Curran, J. A. & Weiss, B. What Is the Impact of mRNA 5' TL Heterogeneity on Translational Start Site Selection and the Mammalian Cellular Phenotype? *FGENE* **7**, 156 (2016).
59. Gandin, V. *et al.* nanoCAGE reveals 5' UTR features that define specific modes of translation of functionally related MTOR-sensitive mRNAs. *Genome Res.* **26**, 636–648 (2016).
60. Lackford, B. *et al.* Fip1 regulates mRNA alternative polyadenylation to promote stem cell self-renewal. *EMBO J* **33**, 878–889 (2014).
61. Hoque, M. *et al.* Analysis of alternative cleavage and polyadenylation by 3' region extraction and deep sequencing. *Nat Meth* **10**, 133–139 (2012).
62. Ji, Z., Lee, J. Y., Pan, Z., Jiang, B. & Tian, B. Progressive lengthening of 3' untranslated regions of mRNAs by alternative polyadenylation during mouse embryonic development. *Proc. Natl. Acad. Sci. U.S.A.* **106**, 7028–7033 (2009).

63. Mayr, C. & Bartel, D. P. Widespread Shortening of 3'UTRs by Alternative Cleavage and Polyadenylation Activates Oncogenes in Cancer Cells. *Cell* **138**, 673–684 (2009).
64. Sandberg, R., Neilson, J. R., Sarma, A., Sharp, P. A. & Burge, C. B. Proliferating Cells Express mRNAs with Shortened 3' Untranslated Regions and Fewer MicroRNA Target Sites. *Science* **320**, 1643–1647 (2008).
65. Xia, Z. *et al.* Dynamic analyses of alternative polyadenylation from RNA-seq reveal a 3'-UTR landscape across seven tumour types. *Nat Comms* **5**, 5274 (2014).
66. Movassat, M. *et al.* Coupling between alternative polyadenylation and alternative splicing is limited to terminal introns. *RNA Biol* **13**, 646–655 (2016).
67. Elkon, R., Ugalde, A. P. & Agami, R. Alternative cleavage and polyadenylation: extent, regulation and function. *Nat Rev Genet* **14**, 496–506 (2013).
68. Besser, D. Expression of Nodal, Lefty-A, and Lefty-B in Undifferentiated Human Embryonic Stem Cells Requires Activation of Smad2/3. *Journal of Biological Chemistry* **279**, 45076–45084 (2004).
69. Wu, J. & Izpisua Belmonte, J. C. Dynamic Pluripotent Stem Cell States and Their Applications. *Cell Stem Cell* **17**, 509–525 (2015).
70. Ávila-González, D. *et al.* Capturing the ephemeral human pluripotent state. *Dev. Dyn.* **245**, 762–773 (2016).
71. Hayashi, Y. & Furue, M. K. Biological Effects of Culture Substrates on Human Pluripotent Stem Cells. *Stem Cells International* **2016**, 1–11 (2016).
72. Hannoun, Z. *et al.* The Comparison between Conditioned Media and Serum-Free Media in Human Embryonic Stem Cell Culture and Differentiation. *Cellular Reprogramming (Formerly "Cloning and Stem Cells")* **12**, 133–140 (2010).
73. Strizzi, L. *et al.* Effects of a novel Nodal-targeting monoclonal antibody in melanoma. *Oncotarget* **6**, 34071–34086 (2015).
74. Gore, A. V., Cheong, A., Gilligan, P. C. & Sampath, K. Gore *et al.* reply. *Nature* **450**, E2–E4 (2007).
75. Kumari, P. *et al.* An essential role for maternal control of Nodal signaling. *eLife* **2**, 31–23 (2013).
76. Lim, S. *et al.* Dorsal activity of maternal squint is mediated by a non-coding function of the RNA. *Development* **139**, 2903–2915 (2012).
77. Costa, F. F. *et al.* Epigenetically reprogramming metastatic tumor cells with an embryonic microenvironment. *Epigenomics* **1**, 387–398 (2009).
78. Hardy, K. M. *et al.* Regulation of the Embryonic Morphogen Nodal by Notch4 Facilitates Manifestation of the Aggressive Melanoma Phenotype. *Cancer Research* **70**, 10340–10350 (2010).
79. Hardy, K. M. *et al.* Targeting nodal in conjunction with dacarbazine induces synergistic anticancer effects in metastatic melanoma. *Mol. Cancer Res.* **13**, 670–680 (2015).
80. Postovit, L.-M. *et al.* Human embryonic stem cell microenvironment suppresses the tumorigenic phenotype of aggressive cancer cells. *Proc. Natl. Acad. Sci. U.S.A.* **105**, 4329–4334 (2008).
81. de Klerk, E. & t Hoen, P. A. C. Alternative mRNA transcription, processing, and translation: insights from RNA sequencing. *Trends in Genetics* **31**, 128–139 (2015).
82. Wang, E. T. *et al.* Alternative isoform regulation in human tissue transcriptomes. *Nature* **456**, 470–476 (2008).
83. Tian, B. A large-scale analysis of mRNA polyadenylation of human and mouse genes.

- Nucleic Acids Research* **33**, 201–212 (2005).
84. Derti, A. *et al.* A quantitative atlas of polyadenylation in five mammals. *Genome Res.* **22**, 1173–1183 (2012).
85. Yang, X. *et al.* Widespread Expansion of Protein Interaction Capabilities by Alternative Splicing. *Cell* **164**, 805–817 (2016).
86. Crooks, G. E., Hon, G., Chandonia, J.-M. & Brenner, S. E. WebLogo: a sequence logo generator. *Genome Res.* **14**, 1188–1190 (2004).
87. Schneider, T. D. & Stephens, R. M. Sequence logos: a new way to display consensus sequences. *Nucleic Acids Research* **18**, 6097–6100 (1990).
88. Welch, D. R. *et al.* Characterization of a highly invasive and spontaneously metastatic human malignant melanoma cell line. *Int. J. Cancer* **47**, 227–237 (1991).
89. Corbisier, P. *et al.* DNA copy number concentration measured by digital and droplet digital quantitative PCR using certified reference materials. *Anal Bioanal Chem* **407**, 1831–1840 (2015).
90. Borson, N. D., Salo, W. L. & Drewes, L. R. A lock-docking oligo(dT) primer for 5' and 3' RACE PCR. *PCR Methods Appl.* **2**, 144–148 (1992).

Acknowledgements

This work was supported by an Alberta Innovates Health Solutions Translational Health Chair in cancer and by the Sawin-Baldwin Chair and the Dr. Anthony Noujaim chair from WCHRI and the ACF awarded to LMP.

Author Contribution Statement

Conceived and designed the experiments: SDF and LMP. Performed the experiments: SDF. Analyzed the data: SDF. Wrote the paper: SDF and LMP. Reviewed and approved the final manuscript: SDF and LMP.

Figures and legends:

Figure 1: NODAL mRNA levels can vary dramatically between sub cultures of hES cells.

a) ddPCR droplet plots for examples of “high” and “low” total NODAL expression in H9 hES cells using a primer probe assay spanning the exon 1 - exon 2 junction. “RT” = reverse transcriptase. Blue droplets are positive for NODAL target, and black droplets are negative. The pink line indicates amplitude threshold for a positive call. b) Top: Quantification of total NODAL levels from A. Bottom: Both “high” and “low” NODAL samples were positive for markers of pluripotency using end-point RT PCR. “-” = no template control. c) “mT” = H9 hES cells previously adapted to culture in defined mTESR-1. “CM” = H9 hES cells cultured in MEF-conditioned media for several passages. Arrows indicate transitions to different media. Error bars in b and c indicate 95% confidence interval for Poisson-calculated copies of transcript detected. d) Expression of pluripotency markers was not lower in mTESR-1 relative to MEF- CM culture conditions. Error bars indicate standard deviations. e) Representative images of hES cells cultured in mTESR-1 (top) and MEF-CM (bottom) at increasing magnifications (left to right). Scale bars are shown.

Figure 2: A genetically regulated splice variant is expressed by a subset of human pluripotent stem cells.

Top: a schematic of the human *NODAL* gene is shown in grey. Diagram scale is approximate. Bottom left: the resulting splice variants are shown for different rs2231947 genotypes. Constitutively spliced exons are shown in yellow. The alternatively spliced exon is shown in blue. Bottom right: sequence “web logs” show human *NODAL* rs2231947 locus (top) relative to information content (middle) and nucleotide frequency (bottom) of human splice donor sites. Position “0” marks the exon-intron boundary and is the first (most 5') base of an intron.

Figure 3: RLM 5' RACE reveals a relatively uniform 5' UTR, while 3' RACE reveals alternative polyadenylation of NODAL transcripts.

NODAL transcript schematics are shown at the top of each panel indicating the region of interest (“?”) and primers used for a, b, and d. “R1” = first reverse primer. “R2” = nested reverse primer. “F1” = first forward primer. “F2” = nested forward primer. “RT” = reverse transcription primer. “—//” indicates continuation of the transcript beyond what is shown. Adapter primer sites are not shown. a) Top: A single major 5' end product was found for H9 and H1 hES cells. “TAP” = Tobacco Acid Pyrophosphatase. Bottom: Alignments of the major product 5' end (“short”) and a minor product 5' end (“alt_long,” see Supplementary Fig. S2) to the *NODAL* locus. Relevant tracks from the human genome browser are also shown, including Cap Analysis of Gene Expression (CAGE) read alignments that closely match both 5' ends obtained in our RLM 5' RACE analysis, and H3K4-trimethylation density in H1 hES cells. b) 3' transcript end analysis reveals roughly equal utilization of two NODAL polyadenylation sites. c) These sites map to the two more proximal of three “canonical” polyadenylation sites (“PAS”) defined by A[A/T]TAAA motifs in the annotated NODAL 3' UTR. d) and e) The same analysis reveals polyadenylation of NODAL variant transcripts at the same two sites, but with usage skewed heavily toward the more distal site. Constitutive exons are shown in yellow and the alternative cassette exon (“ALT”) is shown in blue. “AAAA...” represents the polyA tail at the 3' end of transcripts. Exons upstream (5') of the alternative exon or exon 3 are not shown.

Figure 4: A natural antisense transcript (NAT) and circular RNA share sequence with and confound detection of NODAL's second exon.

a) NODAL detection across different regions of the full-length transcript. b) Design of ddPCR assay to specifically detect the NAT. c) Quantification of NAT. Blue dots represent positive droplets. Black dots represent negative droplets. "RT" = reverse transcriptase. d) Locations of Alu SINE elements are shown relative to the *NODAL* gene. Arrows indicate orientation/strand of Alu elements. e) Left: End-point PCR detection of circular exon 2 amplicons (and products resulting from template switching) using two different primer sets in two different H9 hES samples ("1" and "2"). "NTC" = no template control. Images were inverted for better visualization of bands. Right: Schematic of NODAL exon 2 circular RNA and PCR strategy used. Red bars indicate PCR amplicons. "x" indicates non-productive amplification of linearly-spliced exon 2. "SA" = splice acceptor. "SD" = splice donor. For all schematics, NODAL exon 2 is shown in blue and the NAT in orange. "F" = forward primer. "R" = reverse primer. "x" indicates no primer binding site in full-length NODAL transcripts. "FAM" = fluorescent probe.

Figure 5: Profiling of *NODAL* locus transcripts using ddPCR.

a) Approximate target location for ddPCR assays used to quantify transcripts expressed from the *NODAL* locus. Full-length *NODAL* is shown in blue, and the NAT in orange. Arrows indicate approximate location of forward and reverse primers only. For simplicity, locations of fluorescent probes are not shown. b) Quantification of all *NODAL* locus transcripts in parallel. The bottom chart illustrates the same data as the top, but plotted on a log₁₀ scale. “231” = MDA-MB-231. Error bars indicate 95% confidence intervals of Poisson-calculated target copies.